Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuki Nishimura

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Oncology|October 15, 2023
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver MetastasesKyosuke Nishio, Takuya Higashio, Kazumasa Komura, et al.
Japanese Journal of Clinical Oncology|October 19, 2025
Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan ConsortiumTaizo Uchimoto, Kensuke Hirosuna, Heima Niigawa, et al.
Japanese Journal of Clinical Oncology|March 12, 2026
Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysisKazuki Nishimura, Kensuke Hirosuna, Heima Niigawa, et al.
Targeted Oncology|May 28, 2024
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Takuya Matsuda, Kazumasa Komura, et al.
World Journal of Urology|February 24, 2025
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impactTatsuo Fukushima, Takuya Tsujino, Moritoshi Sakamoto, et al.
Targeted Oncology|March 28, 2024
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint InhibitorsTaizo Uchimoto, Shuya Tsuchida, Kazumasa Komura, et al.
The Prostate|March 31, 2026
A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate CancerKoichiro Kurokawa, Satoshi Yamamoto, Yasutaka Yamada, et al.
International Journal of Clinical Oncology|January 31, 2025
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortiumTaizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, et al.
Japanese Journal of Clinical Oncology|May 17, 2025
Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center studyYosuke Kinoshita, Yasutaka Yamada, Takuya Tsujino, et al.
BJU International|November 13, 2025
Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosisTomoki Shirafuji, Yasutaka Yamada, Kodai Sato, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Oncology|October 15, 2023
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver MetastasesKyosuke Nishio, Takuya Higashio, Kazumasa Komura, et al.
Japanese Journal of Clinical Oncology|October 19, 2025
Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan ConsortiumTaizo Uchimoto, Kensuke Hirosuna, Heima Niigawa, et al.
Japanese Journal of Clinical Oncology|March 12, 2026
Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysisKazuki Nishimura, Kensuke Hirosuna, Heima Niigawa, et al.
Targeted Oncology|May 28, 2024
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Takuya Matsuda, Kazumasa Komura, et al.
World Journal of Urology|February 24, 2025
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impactTatsuo Fukushima, Takuya Tsujino, Moritoshi Sakamoto, et al.
Targeted Oncology|March 28, 2024
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint InhibitorsTaizo Uchimoto, Shuya Tsuchida, Kazumasa Komura, et al.
The Prostate|March 31, 2026
A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate CancerKoichiro Kurokawa, Satoshi Yamamoto, Yasutaka Yamada, et al.
International Journal of Clinical Oncology|January 31, 2025
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortiumTaizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, et al.
Japanese Journal of Clinical Oncology|May 17, 2025
Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center studyYosuke Kinoshita, Yasutaka Yamada, Takuya Tsujino, et al.
BJU International|November 13, 2025
Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosisTomoki Shirafuji, Yasutaka Yamada, Kodai Sato, et al.
Pageof 7